Advanced search
Publication Cover
Expert Review of Hematology Volume 5, 2012 - Issue 2
Submit an article Journal homepage
8
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluations

Are reduced-intensity transplants safe in older patients with hematologic malignancies?

Rachel E Protheroe Bone Marrow Transplant Unit,University Hospitals Bristol, Bristol, UK; Bone Marrow Transplant Unit,University Hospitals Bristol, Bristol, UK
&
David I Marks Bone Marrow Transplant Unit,University Hospitals Bristol, Bristol, UK; Department of Adult Bone Marrow Transplantation, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8BJ, UK. [email protected]; Department of Adult Bone Marrow Transplantation, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8BJ, UK. [email protected]
Pages 149-152 | Published online: 10 Jan 2014

References

  • Sorror ML, Sandmaier BM, Storer BE et al. Long-term outcomes among older patients following non-myeloablative conditioning and allogeneic hematopoietic stem cell transplantation for advanced hematologic malignancies. JAMA 306(17), 1874–1883 (2011).
  • Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8), 2912–2919 (2005).
  • Kahl C, Storer BE, Sandmeier BM et al. Relapse risk in patients with malignant disease given allogeneic hematopoietic cell transplantation after non-myeloablative conditioning. Blood 110(7), 2744–2748 (2007).
  • Burnett AK, Milligan D, Goldstone A et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br. J. Haematol. 145(3), 318–332 (2009).
  • Sorror ML, Giralt S, Sandmaier BM et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 110(13), 4606–4613 (2007).
  • McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumour effects. Blood 97(11), 3390–3400 (2001).
  • Estey E, de Lima M, Tibes R et al. Prospective feasibility analysis of reduced-intensity (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109(4), 1395–1400 (2007).
  • Lim Z, Brand R, Martino R et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J. Clin. Oncol. 28(3), 405–411 (2010).
  • McClune BL, Weisdorf DJ, Pedersen TL et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J. Clin. Oncol. 28(11), 1878–1887 (2010).
  • Koreth J, Aldridge J, Kim H et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advancing age. Biol. Blood Marrow Transplant. 16(6), 792–800 (2010).
  • Klepin HD, Geiger AM, Tooze JA et al. The feasibility of inpatient geriatric assessment for older adults receiving induction therapy for acute myelogenous leukemia. J. Am. Geriatr. Soc. 59(10), 1837–1846 (2011).
  • Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J. Clin. Oncol. 29(25), 3457–3465 (2011).
  • Ho AY, Pagliuca A, Kenyon M et al. Reduced-intensity allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (CAMPATH-1H) (FBC) conditioning. Blood 104(6), 1616–1623 (2004).
  • Kollman C, Howe CW, Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98(7), 2043–2051 (2001).
  • Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl. Int. 22(11), 1041–1050 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.